Drug intelligence / Profile preview

JS112

Development stage: Unknown
Lead developer: Junshi Biosciences
Modality: Small Molecules
Administration: Oral

Overview

JS112 is a small molecule Aurora A inhibitor being developed by Junshi Biosciences for the treatment of advanced solid tumors. Aurora A is a serine/threonine kinase that plays a critical role in cell division, specifically in centrosome maturation, spindle assembly, and chromosome segregation. Overexpression of Aurora A is associated with various cancers and poor prognosis. By inhibiting Aurora A, JS112 aims to disrupt the cell cycle and induce apoptosis in cancer cells. The drug received investigational new drug (IND) application approval from the National Medical Products Administration (NMPA) of China in February 2022 and is currently being evaluated in Phase 1 clinical trials.

Targets

AURKA (Aurora kinase A)

Beyond the preview

Go deeper on JS112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JS112.

Explore the full profile